Fosun Pharma subsidiary gets nod for solid tumor drug trial

Shanghai Fosun Pharmaceutical (Group) Co. announced that its subsidiary, Fosun Pharma Industrial, has received National Medical Products Administration approval for the clinical trial of FXS887 Tablets. This innovative small molecule drug is intended for advanced malignant solid tumors, targeting ATR kinase activity to inhibit tumor cell proliferation. Fosun Pharma Industrial plans to initiate Phase I clinical trials for FXS0887 in China.

As of October 2025, the Group has invested approximately RMB44 million in the research and development of FXS0887. The company noted that as of December 3, 2025, no monotherapy or combination therapy regimens with a small molecule inhibitor targeting the same mechanism have been approved for marketing worldwide. The company cautioned investors about inherent risks in drug R&D, including potential termination of clinical trials due to safety or efficacy concerns.